| Trial | Title | Study Record Detail | Phase | Sponsor/Collaborator |
|---|---|---|---|---|
| DEDN6526A RG7636 | A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma | NCT01522664 | Phase I | Genentech, Inc. |
DEDN6526A (also known as RG7636 or RG-7636) is being developed by Genentech/Roche in using Seattle Genetics ADC technology.
Last Editorial Review: July 29, 2016
